Detalhe da pesquisa
1.
An Immune Atlas of Clear Cell Renal Cell Carcinoma.
Cell
; 169(4): 736-749.e18, 2017 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28475899
2.
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Nature
; 610(7930): 161-172, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171284
3.
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
Blood
; 143(1): 57-63, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37824808
4.
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood
; 143(21): 2152-2165, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437725
5.
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
J Immunol
; 200(7): 2304-2312, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453281
6.
Engineering therapeutic bispecific antibodies using CrossMab technology.
Methods
; 154: 21-31, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30453028
7.
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Cancer Immunol Immunother
; 66(1): 129-140, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27858101
8.
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Eur J Haematol
; 97(5): 461-470, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993060
9.
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.
J Immunol
; 192(5): 2252-60, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24489098
10.
Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.
Nat Biomed Eng
; 8(4): 345-360, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114742
11.
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
Med
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593812
12.
Securin and separase modulate membrane traffic by affecting endosomal acidification.
Traffic
; 12(5): 615-26, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272169
13.
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.
Haematologica
; 103(2): e78-e81, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079598
14.
Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies.
Nat Commun
; 14(1): 7888, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036503
15.
Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation.
Elife
; 122023 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127790
16.
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Clin Cancer Res
; 29(21): 4449-4463, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379429
17.
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
J Clin Invest
; 133(13)2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37219943
18.
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.
Oncoimmunology
; 11(1): 2083479, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35694193
19.
The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
Cell Rep
; 41(3): 111430, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261015
20.
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
J Pharm Sci
; 111(4): 1208-1218, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953862